COMP <GO>
BCTX vs ABVC // EV/EBITDA & P/E VALUATION
BriaCell Therapeutics Corp. (NASDAQ) VS. ABVC BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: BCTX 1
— ABVC 1
■ METRIC PARITY
LAST: $3.31 (-5.43%) • MKT CAP: $28.9M
valuation
—
LAST: $1.04 (-4.59%) • MKT CAP: $27.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCTX VS. ABVC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCTX | ABVC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.76% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 1/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.2 | 48.3 | -17.04 | ABVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $28.9M | $27.8M | $1.1M | BCTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCTX REV | ABVC REV | BCTX GROSS % | ABVC GROSS % | BCTX FCF | ABVC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$28.2M | -$3.0M |
| FY 2024 | $0 | $509.6K | — | 98.0% | -$24.6M | -$1.8M |
| FY 2023 | $0 | $152.4K | — | — | -$23.7M | -$4.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCTX // BETA —
ABVC // BETA —